Form 4: Ultragenyx Executive John Richard Pinion Reports Stock Transactions

John Richard Pinion, an executive at Ultragenyx Pharmaceutical Inc., reported the acquisition and disposal of company stock and derivative securities.

Summary

• On March 1, 2024, John Richard Pinion, EVP, Chief Quality Operations Officer of Ultragenyx Pharmaceutical Inc., reported several transactions involving the company's stock.
• These transactions included the acquisition of 17,800 shares of common stock through the award of Restricted Stock Units (RSUs) and 957 shares through the conversion of performance stock units.
• Pinion also disposed of 60 shares to cover tax withholdings related to the vesting of RSUs at a price of $53.69 per share, and sold 4,173 shares at $53.76 per share, also to cover tax withholdings.
• Following these transactions, Pinion beneficially owns 89,268 shares of common stock.
• Additionally, Pinion was granted an option to buy 31,400 shares of common stock at an exercise price of $53.69, which vests over four years.
• After the reported transactions, Pinion holds options for 31,400 shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The transactions are routine and related to executive compensation. There are no explicit positive or negative signals about the company's performance.

Positives

• The acquisition of 17,800 shares through RSUs indicates a long-term incentive for the executive.
• The conversion of 957 performance stock units into common stock suggests the achievement of performance metrics.
• The grant of an option to buy 31,400 shares aligns the executive's interests with the company's future performance.

Negatives

• The sale of 4,173 shares to cover tax withholdings, while common, reduces the executive's direct stake in the company.

Risks

• The vesting schedule of the RSUs and stock options could influence the executive's decisions regarding their tenure with the company.
• Future fluctuations in the stock price could impact the value of the executive's holdings and potentially influence their actions.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting schedules of the RSUs and stock options suggest a multi-year commitment from the executive.

Industry Context

Executive stock transactions are a common occurrence in publicly traded companies and are often related to compensation and incentive plans. These transactions can provide insights into an executive's perspective on the company's performance and future prospects.

Comparison to Industry Standards

• Executive compensation packages, including stock options and RSUs, are standard practice among pharmaceutical companies like Ultragenyx to incentivize performance and retain key personnel.
• Vesting schedules for stock options and RSUs typically range from three to five years, aligning with industry norms.
• The reported transactions are similar to those seen at comparable companies such as BioMarin Pharmaceutical and Vertex Pharmaceuticals, where executives regularly report stock acquisitions and disposals related to compensation plans.

Stakeholder Impact

• The transactions have a minimal direct impact on stakeholders, as they are related to executive compensation and do not significantly alter the company's financial position.
• Shareholders may view the transactions as a standard part of executive compensation and incentive alignment.

Key Dates